Stay updated on COMBI-AD Trial: Dabrafenib + Trametinib in Melanoma
Sign up to get notified when there's something new on the COMBI-AD Trial: Dabrafenib + Trametinib in Melanoma page.

Latest updates to the COMBI-AD Trial: Dabrafenib + Trametinib in Melanoma page
- CheckyesterdayNo Change Detected
- Check9 days agoNo Change Detected
- Check16 days agoChange DetectedThe study record history now includes a newer submitted version dated 2026-04-21 and associated “more information” and results-related sections, indicating the trial’s core metadata and reporting content were updated. It replaces an earlier revision (v3.5.2) reference with the latest revision (v3.5.3), consistent with an updated ClinicalTrials.gov record version.SummaryDifference0.5%

- Check23 days agoChange DetectedAdded revision v3.5.2 and deleted revision v3.5.0.SummaryDifference0.0%

- Check52 days agoChange DetectedIn the log, Revision: v3.5.0 was added and Revision: v3.4.3 was crossed out.SummaryDifference0.0%

- Check59 days agoChange DetectedRevision: v3.4.3 was added, replacing v3.4.2.SummaryDifference0.0%

- Check88 days agoChange DetectedRevision: v3.4.2 was added as the latest version in the study's history, replacing the earlier v3.4.1. The notice about government funding and operating status was removed from the page.SummaryDifference0.3%

- Check95 days agoChange DetectedThe page shows two minor administrative updates: a site-wide notice regarding government funding and a new revision tag (v3.4.1) that supersedes v3.4.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

Stay in the know with updates to COMBI-AD Trial: Dabrafenib + Trametinib in Melanoma
Enter your email address, and we'll notify you when there's something new on the COMBI-AD Trial: Dabrafenib + Trametinib in Melanoma page.